IL17A and inflammatory bowel disease: Comparing patients receiving any IL-17 inhibitor to placebo, there was no difference in the pooled risk of new-onset IBD in the induction studies for both the best-case [RD 0.0001 (95% CI: -0.0011, 0.0013)] and worst-case scenario [RD 0.0008 (95% CI: -0.0005, 0.0022)].